Astrid Borkowski - Feb 8, 2024 Form 4 Insider Report for HilleVax, Inc. (HLVX)

Role
Chief Medical Officer
Signature
/s/ Paul Bavier, Attorney-in-Fact for Astrid Borkowski
Stock symbol
HLVX
Transactions as of
Feb 8, 2024
Transactions value $
-$58,726
Form type
4
Date filed
2/12/2024, 07:35 PM
Previous filing
Dec 18, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction HLVX Common Stock Sale -$58.7K -3.93K -2.38% $14.93 161K Feb 8, 2024 Direct F1, F2
transaction HLVX Common Stock Award $0 +53.6K +33.26% $0.00 215K Feb 8, 2024 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction HLVX Stock Option (Right to Buy) Award $0 +69.9K $0.00 69.9K Feb 8, 2024 Common Stock 69.9K $15.06 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares sold to satisfy tax withholding obligations upon the settlement of restricted stock units ("RSUs"), which sale was mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
F2 The price reported in Column 4 is a weighted average price calculated by the broker executing the sell-to-cover transactions. These shares were sold as part of a block trade in multiple transactions, and the Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate sales price.
F3 Represents RSUs which will vest as to 25% of the total number of RSUs granted on each of the first four anniversaries of February 8, 2024, subject to the reporting person's continuous service to the Issuer on the applicable vesting dates. Each RSU represents a contingent right to receive one share of common stock of the Issuer and the RSUs have no expiration date.
F4 The option is exercisable as it vests. The option will vest with respect to 25% of the shares of common stock on February 8, 2025 and will vest with respect to the remaining shares in equal monthly installments over the following three years subject to the reporting person's continuous service to the Issuer on the applicable vesting dates.